Indiana University   

PUMP-2 trial combined FUDR via HAIP with gemcitabine and cisplatin, no immunotherapy was on the protocol. 

4 months of Neoadjuvant GAP resulted in conversion from unresectable to resectable. 

In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which sys...

How much weight do you give to a hgb/hct threshold versus symptoms?

Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...

Does the 2020 approval of Nivolumab and Ipilimumab for mNSCLC with PDL1 >1% impact your decision?

How do you decide how long to continue?

Pathology is not carcinoid or small cell.

The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...

Would you continue to trend ctDNA to detect early recurrence?

What are the risks of infection with COVID-19 if using immunotherapy?  

Do you ever consider stopping if stable disease and good tolerance?

PET-CT and Brain MRI are negative for other evidence of disease.

What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

Does your approach differ by EBV status?  

Would you give adjuvant chemotherapy or start osimertinib?

Would you offer chemotherapy alone per data from BILCAP or is there any role of radiation?

There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...

How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?